drugset / Trial / NCT00547586
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
Phase 2
Completed
122 enrolled
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
Timeline
- Start
- 2007-10
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylnaltrexone | Other / unclassified | 150 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 300 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 450 mg | Oral |
| Subject | Methylnaltrexone | Other / unclassified | 600 mg | Oral |